Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress
August 7, 2018 3:32 PM EDT
SunTrust Robinson Humphrey lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $61.00 (from $102.00) while maintaining a Buy rating.
Analsyt Edward Nash commented, "Updated data from hemophilia A program dims outlook as shares tumble 28% intraday (vs S&P50 up 0.3%). While the mean... More
August 7, 2018 3:31 PM EDT
Cowen lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $80.00 (from $90.00) while maintaining a Outperform rating.
Analyst Phil Nadeau commented, "Spark reported Q2 financials and provided an update on the SPK-8011 clinical program. Five of seven patients treated with... More
August 7, 2018 9:34 AM EDT
Cantor Fitzgerald analyst Elemer Piros came out to defended Spark Therapeutics (NASDAQ: ONCE) following data, saying while the market expected perfection, they didn't.
Piros commented, "We reiterate our Overweight rating and 12-month PT of $103 on Spark Therapeutics following 2Q18 financial results and program... More
August 7, 2018 8:20 AM EDT
BioMarin Pharma (NASDAQ: BMRN) Climbs Following Hemophilia A Gene Therapy Data from Rival Spark Therapeutics (NASDAQ: ONCE)
...
More
August 7, 2018 7:35 AM EDT
(Updated)
Spark Therapeutics (NASDAQ: ONCE) reported Q2 EPS of ($2.07), $1.97 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $25.2 million versus the consensus estimate of $29 million.
As of July 13, 2018, preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A... More
